NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $57.02 -2.37 (-3.99 %) (As of 02/25/2020 02:16 AM ET) Add Compare Today's Range$55.48Now: $57.02▼$57.7750-Day Range$43.73MA: $57.32▼$62.9052-Week Range$35.41Now: $57.02▼$74.50Volume416,372 shsAverage Volume563,530 shsMarket Capitalization$3.30 billionP/E RatioN/ADividend YieldN/ABeta2.35 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RARE Previous Symbol CUSIPN/A CIK1515673 Webhttp://www.ultragenyx.com/ Phone415-483-8800Debt Debt-to-Equity Ratio0.05 Current Ratio8.24 Quick Ratio8.13Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$103.71 million Price / Sales31.83 Cash FlowN/A Price / Cash FlowN/A Book Value$11.32 per share Price / Book5.04Profitability EPS (Most Recent Fiscal Year)($7.36) Net Income$-402,730,000.00 Net Margins-388.30% Return on Equity-52.36% Return on Assets-40.59%Miscellaneous EmployeesN/A Outstanding Shares57,889,000Market Cap$3.30 billion Next Earnings Date5/4/2020 (Estimated) OptionableOptionable Receive RARE News and Ratings via Email Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:RARE Rates by TradingView Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions What is Ultragenyx Pharmaceutical's stock symbol? Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE." How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) posted its quarterly earnings results on Thursday, February, 13th. The biopharmaceutical company reported ($1.62) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.61) by $0.01. The biopharmaceutical company earned $35.59 million during the quarter, compared to the consensus estimate of $32.31 million. Ultragenyx Pharmaceutical had a negative return on equity of 52.36% and a negative net margin of 388.30%. View Ultragenyx Pharmaceutical's Earnings History. When is Ultragenyx Pharmaceutical's next earnings date? Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Ultragenyx Pharmaceutical. What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings? Ultragenyx Pharmaceutical issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $102-104 million, compared to the consensus revenue estimate of $100.68 million. What price target have analysts set for RARE? 10 brokerages have issued 12 month price targets for Ultragenyx Pharmaceutical's stock. Their forecasts range from $70.00 to $87.00. On average, they expect Ultragenyx Pharmaceutical's stock price to reach $78.13 in the next year. This suggests a possible upside of 37.0% from the stock's current price. View Analyst Price Targets for Ultragenyx Pharmaceutical. What is the consensus analysts' recommendation for Ultragenyx Pharmaceutical? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ultragenyx Pharmaceutical. What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock? Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock: 1. Cowen Inc analysts commented, "Matinas reported 2Q19 with net loss of ($3.6M) and ended the period with $36.8M in cash on the balance sheet. The company should have runway through 2020 and through multiple catalysts; Omega-3 (OM3) asset MAT9001 and antifungal MAT2203 (amphotericin)." (8/15/2019) 2. According to Zacks Investment Research, "Ultragenyx is encouraged by the growing demand for Crysvita from both children and adults, with X-linked hypophosphatemia (XLH) in the United States. The company looks forward to expand the global commercial reach of its approved therapies in 2019. It also expects to file for potential approval of its third therapy, UX007 in fatty acid oxidation disorders in the year. Ultragenyx continues to advance the two gene therapy clinical programs — DTX401 for glycogen storage disease type Ia and DTX301 for ornithine transcarbamylase deficiency — with additional data expected to be released in 2019. However, Since Ultragenyx is a newly commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses and the need for additional capital. Loss estimates have widened ahead of the Q1 earnings results. The company has a positive record of earnings surprises in recent quarters." (4/23/2019) Has Ultragenyx Pharmaceutical been receiving favorable news coverage? News articles about RARE stock have been trending neutral recently, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ultragenyx Pharmaceutical earned a news sentiment score of 0.4 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Ultragenyx Pharmaceutical. Who are some of Ultragenyx Pharmaceutical's key competitors? Some companies that are related to Ultragenyx Pharmaceutical include Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), The Medicines (MDCO) and Horizon Therapeutics (HZNP). What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Exelixis (EXEL), Gilead Sciences (GILD), Portola Pharmaceuticals (PTLA), TG Therapeutics (TGTX), GALAPAGOS NV/S (GLPG), Netflix (NFLX), Sangamo Therapeutics (SGMO), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT) and Vertex Pharmaceuticals (VRTX). Who are Ultragenyx Pharmaceutical's key executives? Ultragenyx Pharmaceutical's management team includes the folowing people: Emil D. Kakkis, President, Chief Executive Officer & DirectorWladimir Hogenhuis, Chief Operating OfficerShalini Sharp, Chief Financial Officer & Executive Vice PresidentDennis Karl Huang, Chief Technical Operations Officer & Senior VPEric Crombez, Chief Medical Officer Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (11.01%), Capital International Investors (10.46%), Capital World Investors (5.60%), State Street Corp (3.81%), FMR LLC (3.16%) and Alliancebernstein L.P. (2.68%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical. Which institutional investors are selling Ultragenyx Pharmaceutical stock? RARE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Group AG, Capital Bank & Trust Co, Rafferty Asset Management LLC, Capital International Inc. CA, Candriam Luxembourg S.C.A., Cubist Systematic Strategies LLC and Laurion Capital Management LP. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Shalini Sharp and Theodore Alan Huizenga. View Insider Buying and Selling for Ultragenyx Pharmaceutical. Which institutional investors are buying Ultragenyx Pharmaceutical stock? RARE stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, Franklin Resources Inc., Alliancebernstein L.P., EcoR1 Capital LLC, First Trust Advisors LP, Pinnacle Associates Ltd., State Street Corp and Barclays PLC. View Insider Buying and Selling for Ultragenyx Pharmaceutical. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Ultragenyx Pharmaceutical's stock price today? One share of RARE stock can currently be purchased for approximately $57.02. How big of a company is Ultragenyx Pharmaceutical? Ultragenyx Pharmaceutical has a market capitalization of $3.30 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis. View Additional Information About Ultragenyx Pharmaceutical. What is Ultragenyx Pharmaceutical's official website? The official website for Ultragenyx Pharmaceutical is http://www.ultragenyx.com/. How can I contact Ultragenyx Pharmaceutical? Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected] MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 712 (Vote Outperform)Underperform Votes: 347 (Vote Underperform)Total Votes: 1,059MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/25/2020 by MarketBeat.com StaffFeatured Article: Dividend Reinvestment Plan (DRIP)
